Ultime notizie per CareDx (NASDAQ:CDNA) Azioni

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

CareDx Inc

CANADIAN TIRE LTD A by Canadian Tire Corp. Ltd.

Canadian Tire Corp Ltd

BTIG analyst Sung Ji Nam maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and lowers the price target from $40 to $35.

News

Price Target

Analyst Ratings

CDNA

BTIG Maintains Buy on CareDx, Lowers Price Target to $35

CareDx now expects full year 2024 non-GAAP gross margin to be approximately 69%, compared to the prior range of 67% to 68%.&nbsp;
CareDx now expects full year 2024 adjusted EBITDA gain to be in the range of $18 million to $22 million, compared to the prior guidance of an adjusted EBITDA gain of $9 million to $15 million.

Guidance

CareDx Raises FY24 Revenue Guidance From $320M - $328M To $327M - $331M, Est $325.969M

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.01 by 1300 percent. This is a 177.78 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $82.88 million which beat the analyst consensus estimate of $80.53 million by 2.93 percent. This is a 23.35 percent increase over sales of $67.19 million the same period last year.

Earnings

Earnings Beats

CareDx Q3 2024 Adj EPS $0.14 Beats $0.01 Estimate, Sales $82.88M Beat $80.53M Estimate

Ark Funds, led by Cathie Wood, is one of the most well-known fund managers thanks to its actively managed ETFs that focus on future growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">areas of innovation.</a>
Two of the fund's ETFs celebrate their 10th anniversaries on Thursday. Here's a look back at the funds' launch and how they've performed over the last 10 years.
Ark Innovation: Wood and<a href="https://www.benzinga.com/topic/ark-funds"> Ark Funds launched</a> the Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) on Oct. 31, 2014. The fund has grown to become the most well-known and largest of the company's funds, with $5.78 billion in assets under management.
"ARRK is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies that are relevant to the Fund's investment theme of disruptive innovation," the company's <a href="https://www.ark-funds.com/funds/arkk">website </a>says.
Disruptive innovation themes include autonomous mobility, precision therapies, next gen cloud, neural networks, intelligent devices, digital wallets, digital assets, smart contracts and multiomic technologies, according to the company.
"ARK defines ‘disruptive innovation' as the introduction of a technologically enabled new product or service that potentially challenges the way the world works."
Here are the current top 10 holdings in the ARKK ETF and their percent of net assets:
<ol>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>Shopify Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
Since the fund's inception, the ETF is up 161.4%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500.
Here's a look at how the returns of ARKK stack up against SPY, which is the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-etf-hits-milestone-as-all-time-highs-conti">oldest and largest </a>U.S. ETF, over time:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>+19.9%</td>
<td>+36.2% </td>
</tr>
<tr>
<td>3-Year</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5-Year</td>
<td>+2.6% </td>
<td>+15.8%</td>
</tr>
<tr>
<td>Since ARKK Inception 10/31/14</td>
<td>+10.2%</td>
<td>+13.2% </td>
</tr>
</tbody>
</table>
</figure>
The chart below from <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro </a>shows the 10-year return of ARKK.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1003" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" alt="" class="wp-image-624517" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" sizes="(max-width: 1003px) 100vw, 1003px" /></a></figure>
For comparison, here is the 10-year chart of the SPY. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" alt="" class="wp-image-624522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Read Next: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">EXCLUSIVE: Cathie Wood Tells Benzinga Why Tesla Should Trade As A Tech Stock</a>
ARK Genomic: The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) was also launched by Ark Funds on Oct. 31, 2014. The fund currently has $1.33 billion in assets under management.
"ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution," the company's <a href="https://www.ark-funds.com/funds/arkg">website </a>says.
Themes for the genomics ETF include precision therapies, multiomic technologies, programmable biology, neural networks, next gen cloud and adaptive robotics, according to the company.
Here are the current top 10 holdings in the ARKG ETF and their percent of net assets:
<ol>
<li>Twist Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>CRISPR Therapeutics: 7.0%</li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
Since the fund's inception, the ETF is up 38.9%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust.
Here's a look at how the returns of ARKG stack up against SPY over time. &nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>-7.9% </td>
<td>+36.2%</td>
</tr>
<tr>
<td>3-Year</td>
<td>-29.9%</td>
<td>+11.8% </td>
</tr>
<tr>
<td>5-Year</td>
<td>-1.9% </td>
<td>+15.8% </td>
</tr>
<tr>
<td>Since ARKG inception 10/31/14</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
Here is the 10-year chart of ARKG. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" alt="" class="wp-image-624525" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Why It's Important: The charts above show that ARKK and ARKG both experiences several years of strong growth and returns for investors, but have underperformed the broader S&amp;P 500 market index in recent years.
The ETFs were once among the most talked about funds, and the company&#8217;s daily trading activity often moved stocks higher, given Wood's outperformance years ago.
While the S&amp;P 500 ETF rebalances quarterly, the actively managed funds complete trades almost every day. Often, the average cost of shares rises over time for stocks that are going up, potentially hurting the gains.
Ark Funds typically invests in companies that it believes will have strong growth over the next five to ten years, which means the funds&#8217; returns can sometimes take years to pay off.
Wood has been early to many themes, including buying shares of NVIDIA Corporation for around $5 in 2014, before the most recent stock split. The fund later sold out of its position in late 2022 and early 2023 and<a href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early"> missed out on huge gains </a>over the last nearly two years.
The fund manager was also early in the Tesla growth story, <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">predicting a $4,000 price target</a> for the electric vehicle company back in February 2018. While Wood was laughed at for the price prediction at the time, the stock would hit the target on a split-adjusted basis in January 2021.
Getting the Tesla prediction right helped elevate Wood's status as a fund manager and led to increased interest in the Ark Funds ETFs.
Although interest in Ark Funds ETFs may have cooled in recent years, many investors still recall their impact and continue to track daily trading activity, watching closely which stocks Wood selects to hold for the next five to 10 years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don&#8217;t?</a></li>
</ul>
Image courtesy of Ark Invest and Shutterstock.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

CareDx, Dovetail Genomics Enter Strategic Partnership To Drive Next Wave Of Innovation In HLA Genotyping For Organ And Stem Cell Transplant Matching

In the preceding three months, 5 analysts have released ratings for CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CareDx and provided 12-month price targets. The average target is $32.2, accompanied by a high estimate of $40.00 and a low estimate of $26.00. This upward trend is apparent, with the current average reflecting a 50.96% increase from the previous average price target of $21.33.
<img src="https://www.benzinga.com/files/images/story/2024/1729602140_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CareDx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CareDx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, CareDx showcased positive performance, achieving a revenue growth rate of 31.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin excels beyond industry benchmarks, reaching -1.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CareDx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For CareDx

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on CareDx

Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CareDx, revealing an average target of $32.2, a high estimate of $40.00, and a low estimate of $26.00. Marking an increase of 50.96%, the current average surpasses the previous average price target of $21.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1729090812_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of CareDx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know CareDx Better</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Breaking Down CareDx's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining CareDx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 31.26% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.51%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CareDx's ROE excels beyond industry benchmarks, reaching -0.54%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CareDx's ROA excels beyond industry benchmarks, reaching -0.3%. This signifies efficient management of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess CareDx: What You Need To Know

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $26 to $35.

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $35

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
The Dow traded down 0.30% to 42,937.44 while the NASDAQ fell 0.84% to 18,347.17. The S&amp;P 500 also fell, dropping, 0.43% to 5,834.67.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 2% on Tuesday.
In trading on Tuesday, energy shares fell by 2.3%.
Top Headline
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported upbeat results for its third quarter.
The company posted adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 21% to $13.78 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 14% to $5.28 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 13% to $8.56 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 43% to $1.4050. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 14% to $26.85 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 14% to $0.1070 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.5% to $70.54 while gold traded up 0.4% at $2,676.80.
Silver traded up 1.2% to $31.69 on Tuesday, while copper fell 1.6% to $4.3360.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 slipped 0.80%, Germany's DAX slipped 0.11% and France's CAC 40 fell 1.05%. Spain's IBEX 35 Index rose 0.67%, while London's FTSE 100 fell 0.52%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ERIC

MGTX

PEGY

SEEL

WOLF

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 89.0% to $1.43 during Tuesday's regular session. The company's market cap stands at $14.4 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 29.25% to $0.07. The company's market cap stands at $8.2 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 20.69% to $8.34. The market value of their outstanding shares is at $49.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares increased by 20.43% to $2.41. The company's market cap stands at $71.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock moved upwards by 19.81% to $5.26. The market value of their outstanding shares is at $64.2 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock moved upwards by 18.36% to $3.03. The market value of their outstanding shares is at $16.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares declined by 45.3% to $1.34 during Tuesday's regular session. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 15.93% to $0.27. The company's market cap stands at $5.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock decreased by 15.26% to $2.69. The company's market cap stands at $78.9 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares decreased by 15.08% to $26.59. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 14.73% to $2.2. The market value of their outstanding shares is at $4.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares decreased by 14.69% to $3.83. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APRE

DWTX

GRTS

IMRX

MYNZ

NIVF

RANI

RBOT

XCUR

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday.
The Dow traded down 0.40% to 42,894.69 while the NASDAQ fell 0.93% to 18,331.05. The S&amp;P 500 also fell, dropping, 0.44% to 5,833.93.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 1.5% on Tuesday.
In trading on Tuesday, energy shares fell by 2%.
Top Headline
Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported revenue of $12.70 billion for the third quarter, beating the consensus of $11.87 billion.
Sales increased 7% Y/Y, reflecting higher net revenues in Global Banking &amp; Markets and Asset &amp; Wealth Management, partially offset by lower net revenues in Platform Solutions. The U.S. financial services giant reported EPS of $8.40, beating the consensus of $7.03.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 27% to $14.41 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 13% to $5.24 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 11% to $8.35 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 52% to $1.1663. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 17% to $25.93 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 18% to $0.1028 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.9% to $70.19 while gold traded up 0.4% at $2,676.10.
Silver traded up 1.2% to $31.700 on Tuesday, while copper fell 1.4% to $4.3425.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.40%, Germany's DAX slipped 0.01% and France's CAC 40 fell 1.10%. Spain's IBEX 35 Index rose 0.64%, while London's FTSE 100 fell 0.37%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday.
Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell sharply in today's pre-market trading as the company <a href="https://www.benzinga.com/quote/CDNA/news">reported preliminary results for the third quarter.</a>
CareDx said it expects third-quarter revenue of $82 million to $83 million, up approximately 23% year over year.
CareDx shares dipped 9% to $28.50 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Qurate Retail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEB#NASDAQ">QRTEB</a>) shares dipped 47.7% to $2.14 in pre-market trading. Qurate Retail will host a conference call to discuss results for the third quarter on Thursday, Nov. 7.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) shares fell 9.7% to $2.04 in pre-market trading after declining around 7% on Monday.</li>
<li>Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) shares declined 7.4% to $10.50 in pre-market trading.</li>
<li>Himalaya Shipping Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NYSE">HSHP</a>) shares fell 6.2% to $7.42 in pre-market trading.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) shares fell 6.2% to $2.90 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 6.1% to $7.05 in pre-market trading.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) shares fell 6% to $41.52 in pre-market trading. Shares of US-listed Chinese stocks traded lower after China&#8217;s September exports missed estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one">Jim Cramer Is Worried About This Plane Maker, Says Palo Alto Is A &#8216;Good&#8217; One</a></li>
</ul>

Pre-Market Outlook

HSHP

JFIN

LSEA

ORGO

QRTEB

CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

CareDx shares are trading lower. The company reported preliminary Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 42.6% to $0.08 during Tuesday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares increased by 21.34% to $0.99. The company's market cap stands at $6.8 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares increased by 19.89% to $0.49. The company's market cap stands at $3.9 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock rose 19.73% to $0.49. The company's market cap stands at $4.4 million. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) stock rose 16.83% to $1.23. The company's market cap stands at $3.6 million. </li>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) shares moved upwards by 12.5% to $1.35. The company's market cap stands at $19.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 11.8% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $2.0 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock declined by 9.91% to $2.82. The market value of their outstanding shares is at $28.9 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock declined by 9.38% to $0.29. The company's market cap stands at $6.3 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares decreased by 9.17% to $28.44. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock decreased by 8.62% to $2.44. The company's market cap stands at $127.7 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares decreased by 7.92% to $0.27. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

ENVB

HOTH

LIPO

NVOS

ONCT

VRPX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<ul>
<li>Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year.</li>
<li>Testing services revenue is expected to be in the range of $60 million to $61 million, an increase of approximately 26% year-over-year. This includes approximately $1.2 million in revenue for tests performed in prior quarters.</li>
<li>Patient and Digital Solutions revenue is expected to be approximately $11.9 million, and Products is expected to be approximately $10.2 million, up 20% and 7% year-over-year, respectively.</li>
<li>Ended the quarter with cash, cash equivalents, and marketable securities of approximately $240 million with no debt.</li>
</ul>

Health Care

General

CareDx Expects Third Quarter 2024 Revenue Of $82M-$83M, Up Approximately 23% YoY, Versus Consensus Of $79.53M

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

IRMD

OMCL

TCMD

TDOC

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

Management

CareDx Has Appointed Jing Huang, In The Newly Created Role Of Chief Data And Artificial Intelligence Officer, Huang Will Lead Key Data Science Initiatives That Are A Part Of The Company's Long-term Strategic Growth Plan

In a Court document unsealed on October 7, 2024, the DOJ indicated that it is declining to intervene in a qui tam action filed by a former CareDx employee.
Today&#39;s decision by the DOJ follows the decision made by the U.S. Securities and Exchange Commission (SEC) in September 2023 to close its investigation and take no action against the Company.
The Company believes the closure of the DOJ&#39;s investigation underscores that the underlying allegations, which have now been reviewed by two separate government agencies, were meritless, reinforcing its confidence in the integrity of its operations.
The qui tam complaint, which was filed under seal on February 12, 2021, in the federal district court for the Eastern District of New York, is now unsealed. CareDx will continue to vigorously defend itself should the former employee choose to proceed with this litigation.

Legal

CareDx Says DOJ Has Concluded Its Investigation With No Finding Of Wrongdoing And Declined To Take Any Further Action; Plans To Defend Itself Should The Former Employee Choose To Proceed With Litigation

CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024.

CareDx Names Keith Kennedy As COO And Jessica Meng As Chief Commercial Officer

Reports Q3 revenue $82.9M, consensus $80.53M. "CareDx (CDNA) had another strong quarter of topline growth and achieved positive adjusted EBITDA for...

CareDx reports Q3 EPS 14c, consensus 1c

FY24 revenue consensus $325.97M. CareDx (CDNA) now expects full year 2024 non-GAAP gross margin to be approximately 69%, compared to the prior rang...

CareDx raises FY24 revenue view $327M-$331M from $320M-$328M

CareDx Non-GAAP EPS of $0.14 beats by $0.13, revenue of $82.88M beats by $2.17M

CareDx, Inc 2024 Q3 - Results - Earnings Call Presentation

CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript

CareDx Inc ( ($CDNA) ) has released its Q3 earnings. Here is a breakdown of the information CareDx Inc presented to its investors. CareDx, Inc., ba...

CareDx Inc. Reports Solid Growth and Raises Guidance

H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx (CDNA – Research Report) today. The company's shares closed yesterday at $22.93....

H.C. Wainwright Sticks to Its Hold Rating for CareDx (CDNA)

Analyst Mark Massaro of BTIG reiterated a Buy rating on CareDx (CDNA – Research Report), reducing the price target to $35.00. Mark Massaro has give...

CareDx: Strong Financial Performance and Strategic Positioning Support Buy Rating Amid Positive Long-Term Growth Prospects

BTIG lowered the firm's price target on CareDx (CDNA) to $35 from $40 but keeps a Buy rating on the shares. The company's Q3 revenue matched its pr...

CareDx price target lowered to $35 from $40 at BTIG

Meeting to be held in Minneapolis on November 13 hosted by Craig Hallum. Published first on TheFly – the ultimate source for real-time, market-movi...

CareDx management to meet with Craig Hallum

Press Releases

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing

CareDx to Host Investor Day on October 15, 2024

CareDx Appoints Jing Huang Chief Data and AI Officer

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

CareDx Reports Preliminary Financial Results for Third Quarter 2024

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting

CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology

Comments

CareDx

Notizie

Ultime notizie per CareDx (NASDAQ:CDNA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO